Overcoming resistance to osimertinib in non-small cell lung cancer: Hopes, doubts, and in-between

Cancer. 2020 Jun 1;126(11):2594-2596. doi: 10.1002/cncr.32810. Epub 2020 Mar 10.

Authors

Antonio Passaro¹, Umberto Malapelle², Ilaria Attili^{1

3

4}, Filippo de Marinis¹

Affiliations

¹ Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy.
² Department of Public Health, University of Naples "Federico II,", Naples, Italy.
³ Istituto Oncologico Veneto, IRCCS, Padova, Italy.
⁴ Department of Surgical, Oncological and Gastroenterological Sciences, University of Padova, Padova, Italy.

PMID: 32154916
DOI: 10.1002/cncr.32810

No abstract available

Keywords: EGFR; NSCLC; lung cancer; osimertinib; resistance.

Publication types

Editorial
Comment

MeSH terms

Acrylamides
Aniline Compounds
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
ErbB Receptors / genetics
Family Characteristics
Genomics
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Mutation
Protein Kinase Inhibitors / therapeutic use

Substances

Acrylamides
Aniline Compounds
Protein Kinase Inhibitors
osimertinib
EGFR protein, human
ErbB Receptors